Polymorphisms of TLR4: Rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles

Clinical Chemistry

Volumn 48, Issue 10, 2002, Pages 1661-1667

  Schmitt, Christopher ^a   Humeny, Andreas ^a   Becker, Cord Michael ^a   Brune, Kay ^a   Pahl, Andreas ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ARTICLE; BACTERIAL INFECTION; CAUCASIAN; DNA POLYMORPHISM; FLUORESCENCE; GENE; GENE FREQUENCY; GENOTYPE; GERMANY; HUMAN; INFECTION SENSITIVITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MONOCYTE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TLR4 GENE;

BACTERIA (MICROORGANISMS);

EID: 0036790341     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.10.1661     Document Type: Article

References (49)

1. From the bench to the bedside: the future of sepsis research. Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop. Chest 1997;111:744-53.
2. Rietschel ET, Brade H. Bacterial endotoxins. Sci Am 1992;267:54-61.
3. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995;13:437-57.
4. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431-3.
5. Janeway CA Jr, Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 1998;10:349-50.
6. Sweet MJ, Hume DA. Endotoxin signal transduction in macrophages. J Leukocyte Biol 1996;60:8-26.
7. Schletter J, Heine H, Ulmer AJ, Rietschel ET. Molecular mechanisms of endotoxin activity. Arch Microbiot 1995;164:383-9.
8. Glauser MP. The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Drugs 1996;52:9-17.
9. Sriskandan S, Cohen J. The pathogenesis of septic shock. J Infect 1995;30:201-6.
10. Darville T, Giroir B, Jacobs R. The systemic inflammatory response syndrome (SIRS): immunology and potential immunotherapy. Infection 1993;21:279-90.
11. Chaby R. Strategies for the control of LPS-mediated pathophysiological disorders. Drug Discov Today 1999;4:209-21.
12. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-43.
13. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-83.
14. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7.
15. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science 1999;284:1313-8.
16. Kopp EB, Medzhitov R. The Toll-receptor family and control of innate immunity. Curr Opin Immunol 1999;11:13-8.
17. Wright SD. Toll, a new piece in the puzzle of innate immunity. J Exp Med 1999;189:605-9.
18. Bowie A, O'Neill LAJ. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukocyte Biol 2000;67:508-14.
19. Muzio M, Polentarutti N, Bosisio D, Prahladan MKP, Mantovani A. Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukocyte Biol 2000;67:450-6.
20. Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999;274:33419-25.
21. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999;274:17406-9.
22. Yang RB, Mark MR, Gray A, Huang A, Xie MH, Zhang M, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998;395:284-8.
23. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274:10689-92.
24. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-8.
25. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999;189:615-25.
26. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting edge: recognition of gram-positive bacterial cell wall components by the innate immune system occurs via toll-like receptor 2. J Immunol 1999;163:1-5.
27. Hirschfeld M, Kirschning CJ, Schwandner R, Wesche H, Weis JH, Wooten RM, et al. Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol 1999;163:2382-6.
28. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285:732-6.
29. Means TK, Wang SY, Lien E, Yoshimura A, Golenbock DT, Fenton MJ. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999;163:3920-7.
30. Kirschning CJ, Wesche H, Ayres TM, Rothe M. Human Toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 1998;188:2091-7.
31. Yang H, Young DW, Gusovsky F, Chow JC. Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4-MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J Biol Chem 2000;275:20861-6.
32. Swantek JL, Tsen MF, Cobb MH, Thomas JA. IL-1 receptor-associated kinase modulates host responsiveness to endotoxin. J Immunol 2000;164:4301-6.
33. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 1998;187:2097-101.
34. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187-91.
35. Lorenz E, Frees KL, Schwartz DA. Determination of the TLR4 genotype using allele-specific PCR. Biotechniques 2001;31:22-4.
36. Humeny A, Bonk T, Berkholz A, Wildt L, Becker CM. Genotyping of thrombotic risk factors by MALDI-TOF mass spectrometry. Clin Biochem 2001;34:531-6.
37. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000;68:6398-401.
38. Kutyavin IV, Afonina IA, Mills A, Gorn W, Lukhtanov EA, Belousov ES, et al. 3′-Minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res 2000;28:655-61.
39. Bonk T, Humeny A. MALDI-TOF-MS analysis of protein and DNA. Neuroscientist 2001;7:6-12.
40. Humeny A, Schiebel K, Seeber S, Becker CM. Identification of polymorphisms within the bovine prion protein gene (Prnp) by DNA sequencing and genotyping by MALDI-TOF-MS. Neurogenetics 2002;4:59-60.
41. Bonk T, Humeny A, Sutter C, Gebert J, von Knebel Doeberitz M, Becker CM. Molecular diagnosis of familial adenomatous polyposis (FAP): genotyping of adenomatous polyposis coli (APC) alleles by MALDI-TOF mass spectrometry. Clin Biochem 2002;35:87-92.
42. Ross P, Hall L, Haft LA. Quantitative approach to single-nucleotide polymorphism analysis using MALDI-TOF mass spectrometry. Biotechniques 2000;29:620-6,628-9.
43. Pusch W, Kraeuter KO, Froehlich T, Stalgies Y, Kostrzewa M. Genotools SNP manager: a new software for automated high-throughput MALDI-TOF mass spectrometry SNP genotyping. Biotechniques 2001;30:210-5.
44. Kang TJ, Chae GT. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol 2001;31:53-8.
45. Channing Laboratory, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School. Programs for Genomic Applications: Innate Immunity in Heart, Lung and Blood Disease. http://innateimmunity.net/ (Accessed July 2002).
46. Heesen M, Blomeke B, Schluter B, Heussen N, Rossaint R, Kunz D. Lack of association between the -260 C→T promoter polymorphism of the endotoxin receptor CD14 gene and the CD14 density of unstimulated human monocytes and soluble CD14 plasma levels. Intensive Care Med 2001;27:1770-5.
47. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumour necrosis factor (TNF) gene poiymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6.
48. Kaijzel EL, Bayley JP, van Krugten MV, Smith L, van de Linde P, Bakker AM, et al. Allele-specific quantification of tumor necrosis factor α (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2001;2:135-44.
49. Lorenz E, Schwartz DA, Martin PJ, Gooley T, Lin MT, Chien JW, et al. Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:384-7.